SEC Form 4 · accession 0000899243-15-006426
ZOGENIX, INC. · ZGNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gail M Farfel
Officer — EVP/Chief Development Officer
Period of report
Oct 5, 2015
Accepted (ET)
Oct 7, 2015 · 4:15 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001375151
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $13.32 | Oct 5, 2015 | A | 15,000 | A | — | Oct 4, 2025 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1The option was granted on October 5, 2015, which is the vesting commencement date. One-half of the shares subject to the option will vest in thirty-six equal monthly installments over the three-year period following the vesting commencement date, subject to the Reporting Person's continued employment with the Company on each vesting date. The remaining one-half of the shares subject to the option will vest based on the following performance milestone: the U.S. Food and Drug Administration's acceptance of the Company's New Drug Application for ZX008 on or before the three-year anniversary of the date of grant, subject to the Reporting Person's continued employment with the Company on such vesting date.